Companies MapLight Therapeutics, Inc.
MapLight Therapeutics (MPLT): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Email me MapLight Therapeutics, Inc.’s executive pay brief as a PDF
It arrives in about 2 minutes, with every figure cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $25,624,254FY2025
CEO total pay was $25,624,254 in fiscal 2025; the brief holds no earlier figure for this CEO.
FY2025: salary $655,250 · bonus $0 · stock awards $12,296,267 · option awards $12,322,406
Order MPLT
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.
Executives and directors
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Christopher Kroeger | $655,250 | $0 | $12,296,267 | $12,322,406 | $331,000 | $0 | $19,331 | $25,624,254 |
| President and Chief Executive Officer | ||||||||
| Erin Foff | 531,000 | 0 | 2,871,478 | 2,636,670 | 194,000 | 0 | 20,851 | 6,254,000 |
| Chief Medical Officer | ||||||||
| Vishwas Setia | 432,294 | 0 | 3,200,500 | 2,367,617 | 183,000 | 0 | 19,153 | 6,202,564 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Christopher Kroeger | $25,624,254 | — | — | — |
| Erin Foff | 6,254,000 | — | — | — |
| Vishwas Setia | 6,202,564 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
We consider compensation for comparable positions in the market, the historical compensation levels of our executives, individual performance as compared to our expectations and objectives, and our desire to motivate our employees to achieve short- and long-term results that are in the best interests of our stockholders and to incentivize a long-term commitment to our company.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pay Governance LLC |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Erin Foff | Option | 1,290 | 5.55 | — |
| Christopher Kroeger | Option | 3,070 | 5.55 | — |
| Erin Foff | RSU | 11,335 | — | 199,099 |
| Erin Foff | RSU | 21,208 | — | 372,519 |
| Vishwas Setia | RSU | 43,367 | — | 761,741 |
| Erin Foff | RSU | 48,275 | — | 847,950 |
| Christopher Kroeger | RSU | 56,204 | — | 987,223 |
| Erin Foff | RSU | 57,155 | — | 1,003,928 |
| Vishwas Setia | RSU | 72,743 | — | 1,277,731 |
| Erin Foff | Option | 82,619 | 5.55 | — |
| Christopher Kroeger | RSU | 94,017 | — | 1,651,409 |
| Vishwas Setia | Option | 176,031 | 17 | — |
| Erin Foff | Option | 196,035 | 17 | — |
| Erin Foff | RSU | 206,901 | — | 3,634,216 |
| Christopher Kroeger | RSU | 218,094 | — | 3,830,821 |
| Christopher Kroeger | RSU | 225,693 | — | 3,964,298 |
| Vishwas Setia | RSU | 248,513 | — | 4,365,131 |
| Christopher Kroeger | RSU | 853,459 | — | 14,991,007 |
| Christopher Kroeger | Option | 916,164 | 17 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Robert Malenka, M.D., Ph.DIndependent · Not standing for re-election | $7,363 | $1,192,533 | $1,877,755 | — | $140,000 | $3,217,650 |
| Maria WalkerIndependent · Audit (Chair) | 51,841 | 498,968 | 344,374 | — | 0 | 895,183 |
| Timothy Garnett, M.B.B.SIndependent · Compensation (Chair) · Nominating and Corporate Governance | 51,841 | 332,189 | 344,374 | — | 0 | 728,403 |
| Nanna Lüneborg, Ph.DIndependent · Audit · Compensation | 10,584 | 0 | 0 | — | 0 | 10,584 |
| George PavlovIndependent · Board Chair · Compensation · Nominating and Corporate Governance | 9,663 | 0 | 0 | — | 0 | 9,663 |
| Christopher A. Kroeger, M.DEmployee director | — | — | — | — | — | 0 |
| Jim Trenkle, Ph.DIndependent · Audit · Nominating and Corporate Governance (Chair) · Not standing for re-election | 0 | 0 | 0 | — | 0 | 0 |
| Martin BablerIndependent · Newly elected | — | — | — | — | — | — |
| Troy CoxIndependent · Nominating and Corporate Governance · Newly elected | — | — | — | — | — | — |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $131,292 |
| Equity awards (grant-date value) | $2,023,690 |
| All other compensation | $140,000 |
| Total cost of the board | $2,294,982 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names MapLight Therapeutics as a peer
Companies that benchmark against MPLT
No companies currently name MPLT as a compensation peer in their most recent disclosure.
This is the complete answer, not a partial one — the list is never padded.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | MapLight Therapeutics, Inc. | 2025 | Christopher Kroeger | $655,250 | $12,296,267 | $12,322,406 | $331,000 | $25,624,254 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-23 | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-23 | —a |
a. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (16 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Christopher Kroeger. DEF 14A, filed 2026-04-29. Section “SUMMARY COMPENSATION TABLE”. As printed: 25,624,254. View filing ↗
- Section 01, Erin Foff. DEF 14A, filed 2026-04-29. Section “SUMMARY COMPENSATION TABLE”. As printed: 6,254,000. View filing ↗
- Section 01, Vishwas Setia. DEF 14A, filed 2026-04-29. Section “SUMMARY COMPENSATION TABLE”. As printed: 6,202,564. View filing ↗
- Section 07, pay ratio. 10-K, filed 2026-03-26. Section “CEO Pay Ratio”. As printed: —. View filing ↗
- Section 08, Robert Malenka, M.D., Ph.D. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 3,217,650. View filing ↗
- Section 08, Maria Walker. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 895,183. View filing ↗
- Section 08, Timothy Garnett, M.B.B.S. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 728,403. View filing ↗
- Section 08, Nanna Lüneborg, Ph.D. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 10,584. View filing ↗
- Section 08, George Pavlov. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 9,663. View filing ↗
- Section 08, Christopher A. Kroeger, M.D. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Jim Trenkle, Ph.D. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Martin Babler. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: —. View filing ↗
- Section 08, Troy Cox. DEF 14A, filed 2026-04-29. Section “Director Compensation”. As printed: —. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-24. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
- Section 09b board cost (computed). Computed. Cash 131,292 + equity 2,023,690 + all other 140,000 = 2,294,982, summed across the director compensation table rows.
- MapLight Therapeutics, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in MapLight Therapeutics, Inc.'s own proxy. As printed: 25,624,254. View filing ↗